Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Lenvatinib

Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

collaborator

Chonnam National University Hospital

OTHER

collaborator

Seoul National University

OTHER

collaborator

Gangneung Asan Hospital

OTHER

collaborator

Ulsan University Hospital

OTHER

collaborator

Chosun University Hospital

OTHER

collaborator

Dong-A University Hospital

OTHER

collaborator

Bundang CHA Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Yonsei University

OTHER

collaborator

Hanyang University Seoul Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Saint Vincent's Hospital, Korea

OTHER

collaborator

Gyeongsang National University Hospital

OTHER

collaborator

Ewha Womans University

OTHER

collaborator

Chungbuk National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Gachon University Gil Medical Center

OTHER

collaborator

The Catholic University of Korea

OTHER

collaborator

Bucheon St. Mary's Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT06138769 - Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter